Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Nicola Fusco, Umberto Malapelle, Matteo Fassan, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 104

Showing 1-25 of 104 citing articles:

Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 148
Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway
Muhammad Tufail, Jia-Ju Hu, Jie Liang, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 25
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management
Konstantinos Venetis, Roberto Piciotti, Elham Sajjadi, et al.
Cells (2021) Vol. 10, Iss. 6, pp. 1377-1377
Open Access | Times Cited: 60
CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress
Chiara Corti, Konstantinos Venetis, Elham Sajjadi, et al.
Expert Opinion on Investigational Drugs (2022) Vol. 31, Iss. 6, pp. 593-605
Open Access | Times Cited: 54
Endometriosis: Update of Pathophysiology, (Epi) Genetic and Environmental Involvement
Nicolas Monnin, Anne Julie Fattet, Isabelle Koscinski
Biomedicines (2023) Vol. 11, Iss. 3, pp. 978-978
Open Access | Times Cited: 30
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 10
Next-generation sequencing for PTEN testing in HR+/HER2˗ metastatic breast cancer
Nicola Fusco, Umberto Malapelle
Critical Reviews in Oncology/Hematology (2025), pp. 104626-104626
Closed Access | Times Cited: 1
Precision medicine in breast cancer: From clinical trials to clinical practice
Edoardo Crimini, Matteo Repetto, Philippe Aftimos, et al.
Cancer Treatment Reviews (2021) Vol. 98, pp. 102223-102223
Closed Access | Times Cited: 48
Akt Isoforms: A Family Affair in Breast Cancer
Alakananda Basu, Christoffer Briggs Lambring
Cancers (2021) Vol. 13, Iss. 14, pp. 3445-3445
Open Access | Times Cited: 46
Mismatch repair-deficient hormone receptor-positive breast cancers: Biology and pathological characterization
Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, et al.
Cancer Cell International (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 42
Improving HER2 testing reproducibility in HER2-low breast cancer
Elham Sajjadi, Konstantinos Venetis, Mariia Ivanova, et al.
Cancer Drug Resistance (2022) Vol. 5, Iss. 4, pp. 882-888
Open Access | Times Cited: 30
Liquid biopsy: Cell-free DNA based analysis in breast cancer
Konstantinos Venetis, Giulia Cursano, Carlo Pescia, et al.
The Journal of Liquid Biopsy (2023) Vol. 1, pp. 100002-100002
Open Access | Times Cited: 22
Advancement in precision diagnosis and therapeutic for triple-negative breast cancer: Harnessing diagnostic potential of CRISPR-cas & engineered CAR T-cells mediated therapeutics
Vinayak Nayak, Sushmita Patra, Kshitij RB Singh, et al.
Environmental Research (2023) Vol. 235, pp. 116573-116573
Closed Access | Times Cited: 20
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management
Mariia Ivanova, Francesca Porta, Federica Giugliano, et al.
Genes (2023) Vol. 14, Iss. 6, pp. 1160-1160
Open Access | Times Cited: 19
Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)
Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel, et al.
Expert Opinion on Therapeutic Patents (2024) Vol. 34, Iss. 3, pp. 141-158
Closed Access | Times Cited: 7
Correlations of Imaging and Therapy in Breast Cancer Based on Molecular Patterns: An Important Issue in the Diagnosis of Breast Cancer
Oana Maria Burciu, Ioan Sas, Tudor-Alexandru Popoiu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8506-8506
Open Access | Times Cited: 7
Multi-omics integration with weighted affinity and self-diffusion applied for cancer subtypes identification
Xin Duan, Xinnan Ding, Zhuanzhe Zhao
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Low-risk triple-negative breast cancers: Clinico-pathological and molecular features
Nicola Fusco, Elham Sajjadi, Konstantinos Venetis, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 172, pp. 103643-103643
Closed Access | Times Cited: 28
HER2 in Metastatic Colorectal Cancer: Pathology, Somatic Alterations, and Perspectives for Novel Therapeutic Schemes
Mariia Ivanova, Konstantinos Venetis, Elena Guerini‐Rocco, et al.
Life (2022) Vol. 12, Iss. 9, pp. 1403-1403
Open Access | Times Cited: 24
Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis
Justus Rosin, Ella Svegrup, Antonios Valachis, et al.
Breast Cancer Research and Treatment (2023) Vol. 201, Iss. 2, pp. 161-169
Open Access | Times Cited: 14
The progressive trend of modeling and drug screening systems of breast cancer bone metastasis
Hanieh Kolahi Azar, Maliheh Gharibshahian, Mohammadreza Rostami, et al.
Journal of Biological Engineering (2024) Vol. 18, Iss. 1
Open Access | Times Cited: 5
The molecular landscape of breast mucoepidermoid carcinoma
Konstantinos Venetis, Elham Sajjadi, Mariia Ivanova, et al.
Cancer Medicine (2023) Vol. 12, Iss. 9, pp. 10725-10737
Open Access | Times Cited: 11
Computational pathology to improve biomarker testing in breast cancer: how close are we?
Elham Sajjadi, Chiara Frascarelli, Konstantinos Venetis, et al.
European Journal of Cancer Prevention (2023) Vol. 32, Iss. 5, pp. 460-467
Closed Access | Times Cited: 11
PIK3CA mutations in endocrine-resistant breast cancer
Caroline Schagerholm, Stephanie Robertson, Hosein Toosi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Half of most frequently mutated genes in breast cancer are expressed differentially between premenopausal and postmenopausal breast cancer patients
Çağlar Berkel, Ercan Çaçan
Cancer Genetics (2024) Vol. 286-287, pp. 11-17
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top